Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (NASDAQ:AMTI) ("AMT"), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therape

Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end Company continues to bolster cash position to extend runway through clinical and regulatory milestones Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. "Our number one priority remains to

Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)The merger is expected to close by year end 20

JMP Securities initiated coverage of Applied Molecular with a rating of Outperform and set a new price target of $92.00

JMP Securities initiated coverage of Applied Molecular Transport with a rating of Mkt Outperform and set a new price target of $92.00

SVB Leerink reiterated coverage of Applied Molecular Transport with a rating of Outperform and set a new price target of $74.00 from $32.00 previously

4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

15-12G - Applied Molecular Transport Inc. (0001801777) (Filer)

EFFECT - Applied Molecular Transport Inc. (0001801777) (Filer)

POSASR - Applied Molecular Transport Inc. (0001801777) (Filer)

Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pou

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30 years of experience leading global technical operations and quality organizations within the life sciences industry. Ms. Banard will also become a member of the company's Audit Committee. "Charlene is a welcome addition to AMT's Board of Directors, bringing critical technical operations expertise and a strong strategic vision to the organization," said Tahir Mahmood, Ph.D.,

Company continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive leadership team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D. "We are thrilled to welcome Carolyn as the newest member of the executive leadership team at AMT," said Dr. Mahmood. "Car

– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative colitis (UC) < 5 years showed clinical remission rate of 43.8% (7/16) in patients receiving combination versus 15.4% (2/13) in patients receiving adalimumab alone, suggesting combination treatment earlier in the course of disease may be beneficial – AMT-101 appeared safe and well-tolerated – Company will host live conference call and webcast today, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., July 06

SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and

–  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)–  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile–  Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups–  Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis–  Further substantiates potential of AMT-101 and Company's oral biologics platform–  Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Appli

SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

SC 13D/A - Applied Molecular Transport Inc. (0001801777) (Subject)

SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)